Tackling Emerging Co-Infections

人类不断地接触多种病原体，除了少数明确定义的混合感染情景(例如艾滋病毒和结核病)外，人们对混合感染对发病率和死亡率的影响知之甚少。越来越多的证据表明，混合感染很常见，会加剧疾病的严重性，并可能显著恶化预后(例如，流感或新冠肺炎相关的曲霉菌感染)。与耐药病原体的混合感染已被证明增加了另一层复杂性，具有高病死率。我们的目标是整合和利用四个中心的专业知识，这四个中心正在处理主要的病原体组[病毒、细菌、真菌和寄生虫]，以促进英国范围内关于疾病在联合感染中的病理生理影响和机制基础的研究。

Humans are continuously exposed to multiple pathogens yet, with the exception of a few well defined coinfection scenarios (HIV and tuberculosis for example), relatively little is known about the impact of co-infections on morbidity and mortality. There is growing evidence indicating that co-infections are common, exacerbate disease severity and can considerably worsen outcome (Influenza or COVID-19 associated Aspergillus infection for example). Co-infections with drug-resistant pathogens have shown to add another layer of complexity with high case-fatality rates. Our aim is to integrate and exploit the expertise of four Centres that are tackling the major pathogen groups [viruses, bacteria, fungi and parasites] to promote UK-wide research on the pathophysiological impact and mechanistic basis of disease in co-infections.